Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13
Cabaletta Bio -1.26%
Cabaletta Bio CABA | 3.13 | -1.26% |
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:
CABA) with a Overweight and lowers the price target from $14 to $13.
